Product Name :
Purfalcamine
Description:
Purfalcamine is an orally active, selective Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) inhibitor with an IC50 of 17 nM and an EC50 of 230 nM. Purfalcamine has antimalarial activity and causes malaria parasites developmental arrest at the schizont stage.
CAS:
1038620-68-6
Molecular Weight:
528.62
Formula:
C29H33FN8O
Chemical Name:
N2-(4-aminocyclohexyl)-9-(3-fluorophenyl)-N6-[4-(piperidine-1-carbonyl)phenyl]-9H-purine-2,6-diamine
Smiles :
NC1CCC(CC1)NC1=NC(NC2C=CC(=CC=2)C(=O)N2CCCCC2)=C2N=CN(C3=CC(F)=CC=C3)C2=N1
InChiKey:
KRCOMOOXOZSNAJ-UHFFFAOYSA-N
InChi :
InChI=1S/C29H33FN8O/c30-20-5-4-6-24(17-20)38-18-32-25-26(35-29(36-27(25)38)34-23-13-9-21(31)10-14-23)33-22-11-7-19(8-12-22)28(39)37-15-2-1-3-16-37/h4-8,11-12,17-18,21,23H,1-3,9-10,13-16,31H2,(H2,33,34,35,36)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Purfalcamine is an orally active, selective Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) inhibitor with an IC50 of 17 nM and an EC50 of 230 nM. Purfalcamine has antimalarial activity and causes malaria parasites developmental arrest at the schizont stage.|Product information|CAS Number: 1038620-68-6|Molecular Weight: 528.62|Formula: C29H33FN8O|Chemical Name: N2-(4-aminocyclohexyl)-9-(3-fluorophenyl)-N6-[4-(piperidine-1-carbonyl)phenyl]-9H-purine-2,6-diamine|Smiles: NC1CCC(CC1)NC1=NC(NC2C=CC(=CC=2)C(=O)N2CCCCC2)=C2N=CN(C3=CC(F)=CC=C3)C2=N1|InChiKey: KRCOMOOXOZSNAJ-UHFFFAOYSA-N|InChi: InChI=1S/C29H33FN8O/c30-20-5-4-6-24(17-20)38-18-32-25-26(35-29(36-27(25)38)34-23-13-9-21(31)10-14-23)33-22-11-7-19(8-12-22)28(39)37-15-2-1-3-16-37/h4-8,11-12,17-18,21,23H,1-3,9-10,13-16,31H2,(H2,33,34,35,36)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 12.{{Tolfenamic Acid} medchemexpress|{Tolfenamic Acid} COX|{Tolfenamic Acid} Protocol|{Tolfenamic Acid} In Vivo|{Tolfenamic Acid} supplier|{Tolfenamic Acid} Epigenetic Reader Domain} 5 mg/mL (23.{{Tetrahydrocurcumin} site|{Tetrahydrocurcumin} Cytochrome P450|{Tetrahydrocurcumin} Purity & Documentation|{Tetrahydrocurcumin} Data Sheet|{Tetrahydrocurcumin} custom synthesis|{Tetrahydrocurcumin} Autophagy} 65 mM; Need ultrasonic).PMID:33290136 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Purfalcamine has low activity against Toxoplasma gondii calcium-dependent protein kinase 3 (TgCDPK3). Purfalcamine (225, 450 nM) has no effect on the parasitemia in the first 32 hours. After about 40 hours, parasite level remains stable and then begins dropping. Purfalcamine inhibits proliferation with EC50s of 171-259 nM for P. falciparum strains (3D7, Dd2, FCB, HB3 and W2), which indicates effectiveness against drug-resistant parasites. Given that the EC50 value for P. falciparum (3D7) is 230 nM, Purfalcamine shows a therapeutic window ranging from 23-fold to 36-fold (EC50s for CHO=12.33 μM, HEp2=7.235 μM, HeLa=7.029 μM and Huh7=5.476 μM).|In Vivo:|Purfalcamine (10 mg/kg; oral gavage; BID; for 6 days) demonstrates a delay in the onset of parasitemia in treated mice. Purfalcamine (20 mg/kg; orally gavage) exhibits a Cmax of 2.6 μM with a half-life of 3.1 hours.|Products are for research use only. Not for human use.|